NanoVibronix, APOGEPHA Arzneimittel Exploring European Distribution Opportunity

NanoVibronix Inc. has entered into a non-binding letter of intent (the LOI) with APOGEPHA Arzneimittel GmbH in which both companies will analyze the potential for APOGEPHA to distribute NanoVibronix’s UroShield product in Germany and other European markets.
 
With a history that dates back more than a century, APOGEPHA has established itself as a dedicated specialist in urology. Under LOI’s terms, APOGEPHA will commence a comprehensive market evaluation on the way(s) UroShield could fit into the care pathway for patients with long term catheters. The LOI and its subsequent findings aim to help NanoVibronix and APOGEPHA better understand the feasibility of a distribution deal between both companies.
 
“APOGEPHA’s reputation in the field of urology coupled with their intimate knowledge of market access, reimbursement strategies and speed to market decisions, gives us great optimism about UroShield’s potential for success in Europe and APOGEPHA’s pivotal role in its distribution,” NanoVibronix CEO Brian Murphy said. “As a solution for patients who are poorly served though the traditional pharmaceutical route of simple antibiotics, UroShield has the potential to become a true standard of care in Europe, and we look forward to working with APOGEPHA to fully understand and model this opportunity.”
 
NanoVibronix is a medical device company headquartered in Elmsford, N.Y., with research and development in Nesher, Israel, that develops medical devices using its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home without assistance of medical professionals.